Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 65

1.

The Clinical Significance of Occult Gastrointestinal Primary Tumours in Metastatic Cancer: A Population Retrospective Cohort Study.

Hannouf MB, Winquist E, Mahmud SM, Brackstone M, Sarma S, Rodrigues G, Rogan PK, Hoch JS, Zaric GS.

Cancer Res Treat. 2017 Mar 21. doi: 10.4143/crt.2016.532. [Epub ahead of print]

2.

Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.

Babashov V, Begen MA, Mangel J, Zaric GS.

Curr Oncol. 2017 Feb;24(1):e6-e14. doi: 10.3747/co.24.3369. Epub 2017 Feb 27.

3.

Reducing Patient Waiting Times for Radiation Therapy and Improving the Treatment Planning Process: a Discrete-event Simulation Model (Radiation Treatment Planning).

Babashov V, Aivas I, Begen MA, Cao JQ, Rodrigues G, D'Souza D, Lock M, Zaric GS.

Clin Oncol (R Coll Radiol). 2017 Jun;29(6):385-391. doi: 10.1016/j.clon.2017.01.039. Epub 2017 Feb 20.

PMID:
28222957
4.

Financial Incentives and Cervical Cancer Screening Participation in Ontario's Primary Care Practice Models.

Pendrith C, Thind A, Zaric GS, Sarma S.

Healthc Policy. 2016 Aug;12(1):116-28.

PMID:
27585031
5.

Diabetic retinopathy screening with pharmacy-based teleophthalmology in a semiurban setting: a cost-effectiveness analysis.

Coronado AC, Zaric GS, Martin J, Malvankar-Mehta M, Si FF, Hodge WG.

CMAJ Open. 2016 Mar 8;4(1):E95-E102. doi: 10.9778/cmajo.20150085. eCollection 2016 Jan-Mar.

6.

Costs of cervical cancer treatment: population-based estimates from Ontario.

Pendrith C, Thind A, Zaric GS, Sarma S.

Curr Oncol. 2016 Apr;23(2):e109-15. doi: 10.3747/co.23.2598. Epub 2016 Apr 13.

7.

Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary.

Hannouf MB, Winquist E, Mahmud SM, Brackstone M, Sarma S, Rodrigues G, Rogan P, Hoch JS, Zaric GS.

Pharmacogenomics J. 2017 Jun;17(3):286-300. doi: 10.1038/tpj.2015.94. Epub 2016 Mar 29.

PMID:
27019982
8.

Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine.

Zaric GS.

Pharmacoeconomics. 2016 Jul;34(7):635-44. doi: 10.1007/s40273-016-0388-x.

PMID:
26899833
9.

Evaluation of Health Economics in Radiation Oncology: A Systematic Review.

Nguyen TK, Goodman CD, Boldt RG, Warner A, Palma DA, Rodrigues GB, Lock MI, Mishra MV, Zaric GS, Louie AV.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1006-14. doi: 10.1016/j.ijrobp.2015.12.359. Epub 2015 Dec 24. Review.

PMID:
26883562
10.

Does obesity influence labour market outcomes among working-age adults? Evidence from Canadian longitudinal data.

Larose SL, Kpelitse KA, Campbell MK, Zaric GS, Sarma S.

Econ Hum Biol. 2016 Mar;20:26-41. doi: 10.1016/j.ehb.2015.09.007. Epub 2015 Oct 19.

PMID:
26650919
11.

Population-based estimates of survival and cost for metastatic melanoma.

McCarron CE, Ernst S, Cao JQ, Zaric GS.

Curr Oncol. 2015 Oct;22(5):326-32. doi: 10.3747/co.22.2557.

12.

Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada.

Enns EA, Zaric GS, Strike CJ, Jairam JA, Kolla G, Bayoumi AM.

Addiction. 2016 Mar;111(3):475-89. doi: 10.1111/add.13195. Epub 2015 Nov 30.

PMID:
26616368
13.

A microsimulation cost-utility analysis of alcohol screening and brief intervention to reduce heavy alcohol consumption in Canada.

Zur RM, Zaric GS.

Addiction. 2016 May;111(5):817-31. doi: 10.1111/add.13201. Epub 2015 Nov 27.

PMID:
26477518
14.

Identification and survival outcomes of a cohort of patients with cancer of unknown primary in Ontario, Canada.

Kim CS, Hannouf MB, Sarma S, Rodrigues GB, Rogan PK, Mahmud SM, Winquist E, Brackstone M, Zaric GS.

Acta Oncol. 2015 Nov;54(10):1781-7. doi: 10.3109/0284186X.2015.1020965. Epub 2015 Mar 31.

PMID:
25825957
15.

Defining Episodes of Care in Children's Mental Health Using Administrative Data.

Reid G, Stewart SL, Zaric GS, Carter JR, Neufeld RW, Tobon JI, Barwick M, Vingilis ER.

Adm Policy Ment Health. 2015 Nov;42(6):737-47. doi: 10.1007/s10488-014-0609-6.

PMID:
25403258
16.

The Effect of Leisure-Time Physical Activity on Obesity, Diabetes, High BP and Heart Disease Among Canadians: Evidence from 2000/2001 to 2005/2006.

Sarma S, Devlin RA, Gilliland J, Campbell MK, Zaric GS.

Health Econ. 2015 Dec;24(12):1531-47. doi: 10.1002/hec.3106. Epub 2014 Sep 23.

PMID:
25251451
17.

Using price-volume agreements to manage pharmaceutical leakage and off-label promotion.

Zhang H, Zaric GS.

Eur J Health Econ. 2015 Sep;16(7):747-61. doi: 10.1007/s10198-014-0626-0. Epub 2014 Sep 6.

PMID:
25193525
18.

Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer.

Ewara EM, Zaric GS, Welch S, Sarma S.

Curr Oncol. 2014 Aug;21(4):e541-50. doi: 10.3747/co.21.1837.

19.

The effect of physical activity on adult obesity: evidence from the Canadian NPHS panel.

Sarma S, Zaric GS, Campbell MK, Gilliland J.

Econ Hum Biol. 2014 Jul;14:1-21. doi: 10.1016/j.ehb.2014.03.002. Epub 2014 Apr 6.

PMID:
24958450

Supplemental Content

Loading ...
Support Center